Table 2.
Characteristics and anthropometric values of the BMI standard group stratified by body fat percentage.
| Normal (n = 15) | Hidden obesity (n = 40) | P | |
|---|---|---|---|
| Age (yr) | 64 [61–72] | 66 [61–72] | .887 |
| Body weight (kg) | 57.4 [52–62.4] | 64.3 [59.2–69.2] | .002 |
| BMI (kg/m2) | 20.4 [19.3–21.9] | 22.8 [21.4–23.9] | <.001 |
| Development of AIDS | 7 (46.7) | 15 (37.5) | .537 |
| Nadir CD4 (/µL) | 144 [60–160] | 96 [24–203] | .533 |
| Duration since HIV diagnosis (yr) | 13 [10–17] | 10 [3–14] | .140 |
| Duration of ART (mo) | 148 [121–184] | 123 [46–159] | .117 |
| Use of TAF | 7 (46.7) | 27 (67.5) | .157 |
| Key drug | |||
| INSTI | 13 | 36 | |
| NNRTI | 1 | 2 | |
| PI | 1 | 2 | |
| Hypertension treatment | 5 (33.3) | 16 (40.0) | .650 |
| Diabetes treatment | 2 (13.3) | 7 (17.5) | .710 |
| Lipid disorder treatment | 0 | 8 (20.0) | .061 |
| Body fat mass (kg) | 8.8 [8.0–12.1] | 16.1 [13.5–17.7] | <.001 |
| Lean body mass (kg) | 47.2 [44.4–50.7] | 48.2 [45.0–51.0] | .719 |
| Body fat percentage (%) | 15.8 [14.5–17.5] | 24.6-22.8–28.1 | <.001 |
| Grip strength (kg) | 37 [33–42] | 35.5 [28.0–40.0] | .185 |
| Visceral fat level | 4 [3–5] | 7 [6–7] | <.001 |
| SMI (kg/m2) | 7.2 [6.8–7.4] | 7.3 [6.9–7.8] | .218 |
Data are presented as counts (percentages) or median [interquartile range].
Standard group < 20; hidden obesity group ≥ 20.
AIDS = acquired immunodeficiency syndrome, ART = antiretroviral therapy, BMI = body mass index, INSTI = integrase strand transfer inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor, PI = protease inhibitor, SMI = skeletal muscle mass index, TAF = tenofovir alafenamide.